WALVAX(300142)2024-09-03 09:31Group 1: HPV Vaccine Pricing and Market Strategy - The self-paid market price of the bivalent HPV vaccine has been affected by the reduced bid price in the welfare project, while the overall price of other HPV vaccines is expected to remain stable [1] - The company's pricing model considers the pricing and sales of similar products upon listing, disposable income of the target demographic, and competitive pricing of other products [1] - The company aims to maintain an orderly market price system while ensuring reasonable product pricing and leveraging product advantages and brand image [1] Group 2: International Market Expansion and Revenue Growth - The company is actively engaging with multiple potential countries and maintaining close communication with UNICEF and other UN agencies to expedite the overseas export of the bivalent HPV vaccine [2] - In 2023, the company's overseas sales revenue accounted for 22% of the total national vaccine export amount, focusing on rapidly growing regions such as Southeast Asia, the Middle East, North Africa, and South America [2] - The company plans to explore new cooperation models to enhance its position and influence in the international market [2] Group 3: Future Product Development - The company's product development strategy will be dynamically adjusted based on market competition and macroeconomic changes, focusing on upgrading existing products and new product layouts based on mRNA and recombinant protein technologies [2]